SANTA CLARA, Calif.--(BUSINESS WIRE)--Iris BioTechnologies Inc. (OTCBB:IRSB), a life sciences company focused on providing patients, doctors, and clinicians with improved methods of identifying effective treatment solutions, and recipient of the Frost and Sullivan 2008 Technology Innovation Award in Pharmacogenomics, is pleased to announce that the company has been awarded $245,000, the maximum amount given for a grant under the US Qualifying Therapeutic Discovery Project (QTDP) Program.
